10eP Prognostic factors and outcomes of primary CNS lymphoma treated with high-dose methotrexate-based chemotherapy: A 12-year experience from North India
ESMO Rare Cancers · 2026-03 · 5 · 100151
DOI: 10.1016/j.esmorc.2026.100151 ↗Kurz gefasst
Fachartikel in der Zeitschrift ESMO Rare Cancers, 2026-03. Verfasst von P. Rabha und 3 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Rabha, P., Raina, V., Jain, A., & Wisely, J. (2026). 10eP Prognostic factors and outcomes of primary CNS lymphoma treated with high-dose methotrexate-based chemotherapy: A 12-year experience from North India. ESMO Rare Cancers, 5, 100151. https://doi.org/10.1016/j.esmorc.2026.100151
Vancouver
Rabha P, Raina V, Jain A, Wisely J. 10eP Prognostic factors and outcomes of primary CNS lymphoma treated with high-dose methotrexate-based chemotherapy: A 12-year experience from North India. ESMO Rare Cancers. 2026;5:100151. doi:10.1016/j.esmorc.2026.100151
BibTeX
@article{Rabha2026,
author = {Rabha, P. and Raina, V. and Jain, A. and Wisely, J.P.},
title = {10eP Prognostic factors and outcomes of primary CNS lymphoma treated with high-dose methotrexate-based chemotherapy: A 12-year experience from North India},
journal = {ESMO Rare Cancers},
year = {2026},
volume = {5},
pages = {100151},
doi = {10.1016/j.esmorc.2026.100151}
}
EUVIMED